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(20%) doses (mean ages at first Pap and first dose: 17.8 and 15.6 years). Adjusted 
incidences of any cytological abnormality (events per 100 annual person-visits) 
ranged between 11.61 with zero doses and 9.10 with three doses. Incidence rate 
ratios (IRRs) versus zero doses were 0.91 (95% CI: 0.87-0.96), 0.83 (95% CI: 0.80-
0.87), and 0.76 (95% CI: 0.74-0.79) for one, two, and three doses, respectively. For 
histology-confirmed high-grade lesions (CIN2+), IRRs versus zero doses were 0.63 
(95% CI: 0.51-0.77), 0.68 (95% CI: 0.58-0.82), and 0.47 (95% CI: 0.40-0.55) with one, 
two, and three doses, respectively. CONCLUSIONS: HPV vaccination may substan-
tially reduce the risk of cervical abnormalities in real-world settings, even when 
vaccination is incomplete. Policy and clinical efforts should focus on encouraging 
eligible girls to initiate vaccination.
PCN17
PrediCtiNg Phase iii survival outComes usiNg Phase ii trial data iN 
NsClC aNd rCC
Macaulay R., Tan H.
PAREXEL, London, UK
OBJECTIVES: Over 50% of oncology drugs fail in Phase III clinical trials. It remains 
imperative to better define ways of predicting whether a drug will demonstrate 
benefits prior to embarking on Phase III clinical trials. This research aims to explore 
whether Overall Response Rates (ORRs) from Phase II trials can be predictive of 
Phase III trial outcomes. METHODS: Phase III data of any Non-Small Cell Lung 
Cancer (NSCLC) and Renal Cell Carcinoma (RCC) oncologic appraised by the FDA, 
or that had failed Phase III clinical trials, since 2002 was extracted along with its 
corresponding Phase II data. RESULTS: 28 oncologics were identified with both 
Phase II and III readouts (NSCLC: 18, RCC: 10) only 12 (43%) of which met their Phase 
III trial endpoint (NSCLC: 6/18 (33%), RCC: 6/10 (60%)). Phase II ORRs varied from 
0%-61% (mean 26%) and were comparable, on average, to those seen in their cor-
responding Phase III trials (29%). 7/10 (70%) drugs with Phase II ORRs > 30% met their 
primary endpoint vs. only 5/18 (28%) with ORRs ≤ 30%. This threshold is dependent 
on whether the Phase III trial is active or placebo-controlled. For active-controlled 
Phase III trials, 3/4 (75%) met their primary endpoint with Phase II ORRs > 42% vs. 
3/12 (25%) with ORRs ≤ 42%. For placebo-controlled Phase III trials, 3/3 approved with 
Phase II ORRs > 16% versus only 3/9 with ORRs ≤ 16%. CONCLUSIONS: The magni-
tude of ORRs seen in Phase II can be correlated with later Phase III trial success in 
NSCLC and RCC. A higher Phase II ORR threshold applies where comparative benefits 
need to be shown over an active comparator in Phase III as opposed to over placebo. 
Further research can better define if such thresholds apply to other tumor types 
and whether this threshold can predict future Phase III trial failures and successes.
PCN18
ursodeoxyCholiC aNd CheNodeoxyCholiC aCid exert distiNCt 
CytotoxiC effeCts oN ColoN CaNCer Cells
Pavlovic N.1, Stankov K.2, Stanimirov B.1, Stojancevic M.1, Kojic V.3, Bogdanovic G.3, Mikov M.1
1Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia and Montenegro, 2Clinical Center of 
Vojvodina, Novi Sad, Serbia and Montenegro, 3Oncology Institute of Vojvodina, Novi Sad, Serbia 
and Montenegro
OBJECTIVES: Hydrophobicity is the most important determinant of toxicity of bile 
acids (BAs) and depends on the number, position and orientation of hydroxyl groups. 
Ursodeoxycholic acid (UDCA) is a hydrophilic dihydroxy BA, which is formed by 
7β -epimerization of chenodeoxycholic acid (CDCA) in the gut by intestinal bacteria. 
Unlike the other secondary BAs, UDCA exerts antiapoptotic effects by preventing 
oxidative stress. The aim of our study was to analyze the influence of stereochemis-
try of hydroxyl groups on antiproliferative activity of BAs. METHODS: Human colon 
adenocarcinoma HT-29 cells were used to assess the cytotoxicity of CDCA and UDCA 
using colorimetric MTT assay. In order to explain obtained results of MTT assay, 12 
molecular descriptors relevant to polarity, solubility and membrane transport were 
calculated from 3D structures of CDCA and UDCA using VolSurf+ software. RESULTS: 
Studied BAs displayed distinct degrees of cytotoxicity towards HT-29 cancer cells in a 
concentration-dependent manner. Concentrations of CDCA and UDCA that inhibited 
cell growth by 50% (IC50) were 19.6 μ M and 351.9 μ M, respectively. Oxidative stress 
is considered to be the most plausible mechanism of cytotoxicity of BAs, which is 
determined mostly by their hydrophobicity. Calculated molecular descriptor that may 
explain these distinct cytotoxic effects is amphiphilic moment (A), which is defined as 
a vector pointing from the centre of hydrophobic domain to the centre of hydrophilic 
domain. The vector length (5.62 of CDCA and 4.87 of UDCA) determines the ability of 
compound to permeate a membrane. This was additionally substantiated with the 
values of CACO2, SKIN and LgBB descriptors that indicate higher Caco-2 permeability, 
skin permeability and blood-brain barrier distribution of CDCA in comparison to 
UDCA. CONCLUSIONS: More pronounced antiproliferative activity of CDCA in com-
parison to UDCA was observed. We suggest that computational methods exploring the 
physicochemical properties of molecules may help in prediction of their cytotoxicity.
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OBJECTIVES: Rigorous critical appraisal of clinical trials to assess bias and chance 
effects, which can distort trial results, can help evaluate the validity of research find-
ings. In a pre-specified integrated analysis of three phase 3 pivotal trials in patients 
with bone metastases secondary to breast cancer, prostate cancer, and other solid 
tumors or multiple myeloma (N= 5,723), denosumab was reported to be superior to 
ZA for the prevention of SREs, with statistically and clinically significant differences. 
Delfini Group performed critical appraisals of the three individual pivotal trials and 
the integrated analysis. METHODS: Published trials (Lipton et al, EJC, 2012; Stopeck 
et al, JCO, 2010; Henry et al, JCO, 2011, Fizazi et al, Lancet, 2011) were analyzed along 
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OBJECTIVES: To determine for which cancers the largest clinical advancements have 
been made, and to examine the relative health benefits offered by cancer-related 
interventions. METHODS: We used the Tufts Medical Center Cost-Effectiveness 
Analysis Registry to identify cost-utility analyses (CUAs) pertaining to cancer-related 
interventions published from 2002 through 2012. We determined the number of 
CUAs published for each cancer type, and their geographic setting. We also reported 
average incremental quality-adjusted life-year (QALY) gain for the five most studied 
cancer types, and for each cancer type the type of intervention offering largest 
health gains. RESULTS: Of the 3,244 published CUAs, 569 (17%) pertained to cancer. 
CUAs were most often set in the United States (40%), followed by United Kingdom 
(15%), Canada (9%) and Netherlands (4%). The five most studied cancers were breast 
(n= 154, 28%), colorectal (n= 62, 11%), cervical (n= 49, 9%), lung (n= 47, 8%) and prostate 
cancer (n= 46, 8%), for which interventions yielded on average, 0.32, 0.32, 0.06, 0.21, 
0.22 QALY gains, respectively. Among the five most studied cancers, the largest QALY 
gains were found for tertiary prevention interventions (mean 0.3, standard deviation 
(SD) 0.4), e.g., pharmaceuticals and surgeries; followed by secondary prevention (0.2, 
SD 0.4), e.g., diagnostic imaging. We found primary prevention interventions offered 
the smallest QALY gain (0.03, SD 0.08), e.g., immunizations. For breast and cervical 
cancer, pharmaceuticals offered the largest QALY gains, for lung and colorectal 
cancers, surgeries offered the largest QALY gains; and for prostate cancer, diagnos-
tics offered the largest QALY gains. CONCLUSIONS: We found many more CUAs for 
some cancers than for others, and that cancer-related CUAs are most often set in 
the US. The magnitude of QALY gain varied by cancer type. Pharmaceuticals offered 
the largest QALY gains for two of the five most studied cancers, but for other cancer 
types, surgeries and diagnostic imaging offered the largest QALY gains.
PCN14
ComParative effeCtiveNess of everolimus vs. fulvestraNt 
moNotheraPy amoNg PostmeNoPausal womeN with hr+/her2- 
metastatiC breast CaNCer
Lin P.L.1, Hao Y.2, Xie J.3, Li N.1, Ohashi E.1, Koo V.1, Wu E.Q.1
1Analysis Group, Inc., Boston, MA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, 
NJ, USA, 3Analysis Group, Inc., New York, NY, USA
OBJECTIVES: Clinical evidence supports the use of everolimus-based therapy (EVE) 
and of fulvestrant monotherapy (FUL) among postmenopausal women with hor-
mone receptor-positive human epidermal growth factor receptor-2 negative (HR+/
HER2-) metastatic breast cancer (mBC) whose disease progressed on non-steroidal 
aromatase inhibitor (NSAI). However, direct evidence was lacking on the compara-
tive effectiveness of these agents. This study compared progression-free survival 
(PFS) between EVE and FUL in a real-world setting. METHODS: This retrospective 
chart review examined postmenopausal HR+/HER2- mBC patients in community-
based oncology practices who received EVE or FUL (index therapy) for mBC as first-
line, second-line, or third- or later-lines after NSAI. PFS from index therapy initiation 
was assessed and compared using Kaplan-Meier analysis and a Cox proportional 
hazards model adjusting for index therapy line and characteristics at mBC diagnosis 
and index therapy initiation. RESULTS: A total of 192 and 156 patients received EVE 
or FUL, respectively, in a quota-based sample. EVE patients were less likely to have 
bone metastases, more likely to have visceral metastases or to have received prior 
chemotherapy for mBC, and had a shorter duration from initiation of last adjuvant 
endocrine therapy to mBC diagnosis. No significant PFS difference was observed in 
the unadjusted analysis. After adjusting for baseline characteristics, EVE patients 
had significantly longer PFS compared to FUL patients (hazard ratio [HR] = 0.71, 95% 
CI [0.51, 0.99], p = 0.045). When stratified by treatment line, second-line and third- or 
later-line EVE patients had significantly longer PFS (second-line: HR = 0.52, 95% CI 
[0.29, 0.91], p = 0.023; third- or later-lines: HR = 0.48, 95% CI [0.24, 0.93], p= 0.031) than 
FUL patients of the same treatment line. CONCLUSIONS: Among postmenopausal 
women with HR+/HER2- mBC who progressed on NSAI, the use of EVE was associ-
ated with better PFS, particularly on second-, third- and later-lines of treatment.
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OBJECTIVES: Human papillomavirus (HPV) vaccines prevent infection with the 
most cancer-causing HPV types. However, many age-eligible girls do not initiate 
or complete the three-dose regimen. There is limited information on the mag-
nitude of protection provided by partial-vaccination. We sought to empirically 
estimate the effect of HPV vaccination by dose (0, 1, 2 or 3) on cervical abnormality 
rates in a screening cohort of privately-insured U.S. girls (N= 234,829). METHODS: 
We defined a cohort within the MarketScan Commercial Claims database that 
included 9-17 year-olds in 2007 (year of vaccine introduction) who began Pap 
screening during 2008-2013. Follow-up started at subjects’ first-ever Pap and 
ended at abnormality detection or censoring. Treatment group corresponded to 
doses received before the first screening. We used inverse probability of treatment 
weighting to adjust for birth year, age/year of first Pap and first dose, plan type, 
region, zipcode-level socioeconomic factors, and claims-based sexual risk proxies. 
Weighted pooled logistic regressions estimated the effect of dose level on abnor-
mality rates. RESULTS: Subjects received zero (63%), one (8%), two (9%), or three 
